Can serum neurofilament light be a biomarker for multiple sclerosis progression?

Takeaway

  • Changes in serum neurofilament light (sNfL) concentration do not constitute a biomarker for disability progression in patients with secondary progressive multiple sclerosis (SPMS) without inflammation; however, sNfL levels may still be a useful biomarker for other forms of multiple sclerosis (MS).

Why this matters

  • In 2020, the International Progressive MS Alliance stated that sNfL measurements may be a useful biomarker for progressive MS.

  • If sNfL concentration is associated with longitudinal changes in disability in patients with MS, it will be a valuable biomarker for patients with progressive MS.